{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-25-002786","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2025-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.978808+00:00","generated_at":"2026-05-24T04:56:54.168658+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Relmada licenses NDV-01 from Trigone for $3.5M + 3M shares; Phase 2 data at AUA April 2025","bullets":["Upfront: $3.5M cash + 3,017,420 shares (10% of outstanding) for exclusive worldwide rights (ex-India, Israel, S. Africa).","Up to $200M in development/regulatory/sales milestones + 3% royalty on net sales.","NDV-01 is sustained-release gemcitabine/docetaxel for NMIBC; Phase 2 topline data at AUA April 26-29, 2025.","Shares locked up for 12 months; Trigone must vote as board recommends.","Relmada must spend ≥$5M/year on R&D/commercialization from 2026; Trigone can terminate if not."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-25-002786","json":"https://secwatch.observer/filing/0001013762-25-002786.json","markdown":"https://secwatch.observer/filing/0001013762-25-002786.md","text":"https://secwatch.observer/filing/0001013762-25-002786.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000101376225002786/0001013762-25-002786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000101376225002786/ea0235681-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:56:54.168658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}